General References


Yabe D, Nakamura T, Kanazawa N, Tashiro K, Honjo T. Calumenin, a Ca2+-binding protein retained in the endoplasmic reticulum with a novel carboxyl-terminal sequence, HDEF. J Biol Chem 1997; 272:18232-9.

Yabe D, Taniwaki M, Nakamura T, Kanazawa N, Tashiro K, Honjo T. Human calumenin gene (CALU): cDNA isolation and chromosomal mapping to 7q32. Genomics 1998; 49:331-3.

Yadav C, Bajpai M, Kumar V, Ahmed RS, Gupta P, Banerjee BD. Polymorphism in CYP1A1, GSTM 1, GSTT1 genes and organochlorine pesticides in the etiology of hypospadias. Hum Exp Toxicol 2011; 30:1464-74.

Yadav MR, Sabale PM, Giridhar R, Zimmer C, Haupenthal J, Hartmann RW. Synthesis of some novel androstanes as potential aromatase inhibitors. Steroids 2011; 76:464-70.

Yadav S, Dhawan A, Singh RL, Seth PK, Parmar D. Expression of constitutive and inducible cytochrome P450 2E1 in rat brain. Mol Cell Biochem 2006; 286:171-80.

Yadav SS, Ruwali M, Pant MC, Shukla P, Singh RL, Parmar D. Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 genotypes modify the susceptibility to head and neck cancer and treatment response. Mutat Res 2010; 684:49-55.

Yaffe K, Haan M, Byers A et al. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology 2000; 54:1949-54.

Yaffe K, Weston A, Graff-Radford NR et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 2011; 305:261-6.

Yağar S, Yavaş S, Karahalil B. The role of the ADRA2A C1291G genetic polymorphism in response to dexmedetomidine on patients undergoing coronary artery surgery. Mol Biol Rep 2011; 38:3383-9.

Yagasaki F, Jinnai I, Yoshida S et al. Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5; 12)(q31; p13). Genes Chromosomes Cancer 1999; 26:192-202.

Yagihashi T, Mizuno M, Chino B et al. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. Hum Psychopharmacol 2009; 24:301-8.

Yago M, Ohki R, Hatakeyama S, Fujita T, Ishikawa F. Variant forms of upstream stimulatory factors (USFs) control the promoter activity of hTERT, the human gene encoding the catalytic subunit of telomerase. FEBS Lett 2002; 520:40-6.

Yahiaoui S, Pouget C, Buxeraud J, Chulia AJ, Fagnère C. Lead optimization of 4-imidazolylflavans: new promising aromatase inhibitors. Eur J Med Chem 2011; 46:2541-5.

Yakkundi A, McErlane V, Murray M et al. Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. Cancer Gene Ther 2006; 13:598-605.

Yakub I, Lillibridge KM, Moran A et al. Single nucleotide polymorphisms in genes for 2’-5’-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. J Infect Dis 2005; 192:1741-8.

Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 2005; 11:433-9.

Yamada A, Maeda K, Ishiguro N et al. The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet Genomics 2011; 21:523-30.

Yamada H, Ishii Y, Yamamoto M, Oguri K. Induction of the hepatic cytochrome P450 2B subfamily by xenobiotics: research history, evolutionary aspect, relation to tumorigenesis, and mechanism. Curr Drug Metab 2006; 7:397-409.

Yamada K, Hattori E, Iwayama Y. Distinguishable haplotype blocks in the HTR3A and HTR3B region in the Japanese reveal evidence of association of HTR3B with female major depression. Biol Psychiatry 2006; 60:192-201.

Yamada K, Ishiyama-Shigemoto S, Ichikawa F et al. Polymorphism in the 5-prime-leader cistron of the beta-2-adrenergic receptor gene associated with obesity and type 2 diabetes. J Clin Endocr Metab 1999; 84:1754-7.

Yamada K, Watanabe A, Iwayama-Shigeno Y, Yoshikawa T. Evidence of association between gamma-aminobutyric acid type A receptor genes located on 5q34 and female patients with mood disorders. Neurosci Lett 2003; 349:9-12.

Yamada M, Itoh Y, Fujigasaki H et al. A missense mutation at codon 105 with codon 129 polymorphism of the prion protein gene in a new variant of Gerstmann-Straussler-Scheinker disease. Neurology 1993; 43:2723-4.

Yamada M, Itoh Y, Suematsu N, Matsushita M, Otomo E. Lack of an association between apolipoprotein E epsilon-4 and cerebral amyloid angiopathy in elderly Japanese. Ann Neurol 1996; 39:683.

Yamada O, Ozaki K, Furukawa T et al. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. Cell Signal 2011; 23:1119-27

Yamada S, Ding Y, Tanimoto A et al. Apoptosis signal-regulating kinase 1 deficiency accelerates hyperlipidemia-induced atheromatous plaques via suppression of macrophage apoptosis. Arterioscler Thromb Vasc Biol 2011; 31:1555-64.

Yamada S, Richardson K, Tang M et al. Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. Pharmacogenomics J 2010; 10:524-36.

Yamada S, Yasui-Furukori N, Akamine Y, Kaneko S, Uno T. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. Ther Drug Monit 2009; 31:764-8.

Yamada Y, Ando F, Shimokata H. Association of a microsomal triglyceride transfer protein gene polymorphism with blood pressure in Japanese women. Int J Mol Med 2006; 17:83-8.

Yamada Y, Ichihara S, Kato K et al. Genetic risk for metabolic syndrome: examination of candidate gene polymorphisms related to lipid metabolism in Japanese people. J Med Genet 2008; 45:22-8.

Yamada Y, Izawa H, Ichihara S et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347:1916-23.

Yamada Y, Kato K, Oguri M et al. Association of genetic variants with atherothrombotic cerebral infarction in Japanese individuals with metabolic syndrome. Int J Mol Med 2008; 21:801-8.

Yamada Y, Kato K, Oguri M et al. Genetic risk for myocardial infarction determined by polymorphisms of candidate genes in a Japanese population. J Med Genet 2008; 45:216-21.

Yamada Y, Kato K, Yoshida T et al. Association of polymorphisms of ABCA1 and ROS1 with hypertension in Japanese individuals. Int J Mol Med 2008; 21:83-9.

Yamada Y, Matsuo H, Segawa T et al. Assessment of the genetic component of hypertension. Am J Hypertens 2006; 19:1158-65.

Yamada Y, Matsuo H, Warita S et al. Prediction of genetic risk for dyslipidemia. Genomics 2007; 90:551-8.

Yamada Y, Matsuo H, Watanabe S et al. Association of a polymorphism of CYP3A4 with type 2 diabetes mellitus. Int J Mol Med 2007; 20:703-7.

Yamada Y, Metoki N, Yoshida H et al. Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals. Stroke 2008; 39:2211-8.

Yamagata K, Furuta H, Oda N et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature 1996; 384:458-60.

Yamagishi H, Koike T, Ohara S et al. Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers. World J Gastroenterol 2008; 14:2049-54.

Yamagishi K, Tanigawa T, Kitamura A et al. The rs2231142 variant of the ABCG2 gene is associated with uric acid levels and gout among Japanese people. Rheumatology 2010; 49:1461-5.

Yamaguchi H, Calado RT, Ly H et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. New Eng J Med 2005; 352:1413-24.

Yamaguchi H, Sugihara S, Ogawa A, Oshima N, Ihara Y. Alzheimer beta amyloid deposition enhanced by APOE epsilon 4 gene precedes neurofibrillary pathology in the frontal association cortex of non-demented senior subjects. J Neuropathol Exp Neurol 2001; 60:731-9.

Yamaguchi N, Kawaguchi K, Yamamoto N. Study of the mechanism of antihypertensive peptides VPP and IPP in spontaneously hypertensive rats by DNA microarray analysis. Eur J Pharmacol 2009; 620:71-7.

Yamaguchi W, Shinkai T, Inoue Y et al. Association analysis between the C-1291G polymorphism in the promoter region of the adrenergic alpha2A receptor gene and polydipsia in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:499-502.

Yamaguchi Y, Khan KK, He YA, He YQ, Halpert JR. Topological changes in the CYP3A4 active site probed with phenyldiazene: effect of interaction with NADPH-cytochrome P450 reductase and cytochrome b5 and of site-directed mutagenesis. Drug Metab Dispos 2004; 32:155-61.

Yamaji T, Iwasaki M, Sasazuki S, Sakamoto H, Yoshida T, Tsugane S. Methionine synthase A2756G polymorphism interacts with alcohol and folate intake to influence the risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2009; 18:267-74.

Yamajuku D, Okubo S, Haruma T et al. Regular feeding plays an important role in cholesterol homeostasis through the liver circadian clock. Circ Res 2009; 105:545-8.

Yamakawa Y, Hamada A, Nakashima R et al. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit 2011; 33:244-50.

Yamakita M, Ando D, Tang S, Yamagata Z. The Trp64Arg polymorphism of the beta3-adrenergic receptor gene is associated with weight changes in obese Japanese men: a 4-year follow-up study. J Physiol Anthropol 2010; 29:133-9.

Yamamiya I, Yoshisue K, Matsushima E, Nagayama S. Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil. Drug Metab Dispos 2010; 38:1267-76.

Yamamoto A, Lucas J, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell 2000; 101:57-66.

Yamamoto K, Hokimoto S, Chitose T et al. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. J Cardiol 2011; 57:194-201.

Yamamoto K, Matsushita T, Sugiura I et al. Homozygous protein C deficiency: identification of a novel missense mutation that causes impaired secretion of the mutant protein C. J Lab Clin Med 1992; 119:682-9.

Yamamoto M, Abe M, Jin JJ et al. Association of GNB3 gene with pulse pressure and clustering of risk factors for cardiovascular disease in Japanese. Biochem Biophys Res Commun 2004; 316:744-8.

Yamamoto N, Nakayama J, Yamakawa-Kobayashi K, Hamaguchi H, Miyazaki R, Arinami T. Identification of 33 polymorphisms in the adipocyte-derived leucine aminopeptidase (ALAP) gene and possible association with hypertension. Hum Mutat 2002; 19:251-7.

Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 2000; 18:2301-8.

Yamamoto N, Tamura T, Murakami H et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 2005; 23:1061-9.

Yamamoto T, Hagima N, Fukasawa M et al. Metabolism of N,N-dipropyl-2-[4-methoxy-3-(2-phenyl-ethoxy)-phenyl]-ethyl-amine-monohydrochloride (NE-100), a novel sigma ligand: contribution of cytochrome P450 forms involved in the formation of individual metabolites in human liver and small intestine. Drug Metab Pharmacokinet 2003; 18:173-85.

Yamamoto T, Hagima N, Nakamura M, Kohno Y, Nagata K, Yamazoe Y. Differences in cytochrome P450 forms involved in the metabolism of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100), a novel sigma ligand, in human liver and intestine. Drug Metab Dispos 2003; 31:60-6.

Yamamoto T, Hagima N, Nakamura M, Kohno Y, Nagata K, Yamazoe Y. Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl] ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs. Xenobiotica 2004; 34:687-703.

Yamamoto T, Kubota T, Ozeki T et al. Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem. Clin Chim Acta 2005; 362:147-54.

Yamamoto T, Nagafuchi N, Ozeki T et al. CYP3A4*18: it is not rare allele in Japanese population. Drug Metab Pharmacokinet 2003; 18:267-8.

Yamamoto T, Nanba E, Ninomiya H et al. NPC1 gene mutations in Japanese patients with Niemann-Pick disease type C. Hum Genet 1999; 105:10-6.

Yamamoto T, Suzuki A, Kohno Y. Application of microtiter plate assay to evaluate inhibitory effects of various compounds on nine cytochrome P450 isoforms and to estimate their inhibition patterns. Drug Metab Pharmacokinet 2002; 17:437-48.

Yamamoto T, Suzuki A, Kohno Y. High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes. Xenobiotica 2003; 33:823-39.

Yamamoto T, Suzuki A, Kohno Y. High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method. Xenobiotica 2004; 34:87-101.

Yamamoto T, Suzuki A, Kohno Y, Nagata K, Yamazoe Y. Prediction of drug-drug interactions for AUCoral of high clearance drug from in vitro data: utilization of a microtiter plate assay and a dispersion model. Curr Drug Metab 2006; 7:135-46.

Yamamoto Y, Kiyoi H, Nakano Y et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97:2434-9.

Yamamoto Y, Moore R, Hess HA et al. Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. J Biol Chem 2006; 281:16625-31.

Yamamoto Y, Takahashi Y, Nishimura S, Ikumi Y, Mishima N, Kagawa Y. Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy. Yakugaku Zasshi 2011; 131:809-15.

Yamamoto Y, Yamazaki H, Ikeda T et al. Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. Drug Metab Dispos 2002; 30:155-60.

Yamanaka H, Nakajima M, Katoh M et al. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 2004; 14:329-32.

Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990; 29:1322-9.

Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Ikeda M, Ozaki N. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J 2003; 3:356-61.

Yamaori S, Kushihara M, Yamamoto I, Watanabe K. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 2010; 79:1691-8.

Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for cytochrome P450 2D6. Drug Metab Dispos 2011; 39:2049-56.

Yamaori S, Yamazaki H, Iwano S et al. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab Pharmacokinet 2004; 19:120-9.

Yamaori S, Yamazaki H, Iwano S et al. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers. Xenobiotica 2005; 35:69-83.

Yamaori S, Yamazaki H, Suzuki A et al. Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol 2003; 66:2333-40.

Yamasaki T, Izumi S, Ide H, Ohyama Y. Identification of a novel rat microsomal vitamin D3 25-hydroxylase. J Biol Chem 2004; 279:22848-56.

Yamasaki T, Kawamura K, Hatori A et al. PET study on mice bearing human colon adenocarcinoma cells using [11C]GF120918, a dual radioligand for P-glycoprotein and breast cancer resistance protein. Nucl Med Commun 2010; 31:985-93.

Yamasaki Y, Ieiri I, Kusuhara H et al. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther 2008; 84:95-103.

Yamasaki Y, Kishimoto N, Ohnishi H et al. Beta 2-adrenoceptor polymorphism and effects of inhaled beta 2-stimulant (procaterol) and an anti-cholinergic drug (oxitropium) on the airway resistance. Nihon Kokyuki Gakkai Zasshi 2004; 42:239-46.

Yamashiro T, Kuge H, Zhang J, Honke K. Calcineurin mediates the angiotensin II-induced aldosterone synthesis in the adrenal glands by up-regulation of transcription of the CYP11B2 gene. J Biochem 2010; 148:115-23.

Yamashita F, Hara H, Ito T, Hashida M. Novel hierarchical classification and visualization method for multiobjective optimization of drug properties: application to structure-activity relationship analysis of cytochrome P450 metabolism. J Chem Inf Model 2008; 48:364-9.

Yamashita M, Tamasawa N, Matsuki K et al. Insulin suppresses HDL-mediated cholesterol efflux from macrophages through inhibition of neutral cholesteryl ester hydrolase and ATP-binding cassette transporter G1 expressions. J Atheroscler Thromb 2010; 17:1183-9.

Yamashita Y, Kumabe T, Cho YY et al. Fatty acid induced glioma cell growth is mediated by the acyl-CoA synthetase 5 gene located on chromosome 10q25. 1-q25. 2, a region frequently deleted in malignant gliomas. Oncogene 2000; 19:5919-25.

Yamatsuji T, Matsui T, Okamoto T et al. G protein-mediated neuronal DNA fragmentation induced by familial Alzheimer’s disease-associated mutants of APP. Science 1996; 272:1349-52.

Yamauchi T, Kamon J, Waki H et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278:2461-8.

Yamazaki H, Gillam EM, Dong MS, Johnson WW, Guengerich FP, Shimada T. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions. Arch Biochem Biophys 1997; 342:329-37.

Yamazaki H, Guo Z, Persmark M et al. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol Pharmacol 1994; 46:568-77.

Yamazaki H, Hiroki S, Urano T, Inoue K, Shimada T. Effects of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes. Xenobiotica 1996; 26:1143-53.

Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 1997; 283:434-42.

Yamazaki H, Kiyotani K, Tsubuko S et al. Two novel haplotypes of CYP2D6 gene in a Japanese population. Drug Metab Pharmacokinet 2003; 18:269-71.

Yamazaki H, Kuribayashi S, Inoue T et al. Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry. Chem Res Toxicol 2010; 23:152-8.

Yamazaki H, Nakajima M, Nakamura M et al. Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes. Drug Metab Dispos 1999; 27:999-1004.

Yamazaki H, Nakamura M, Komatsu T et al. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr Purif 2002; 24:329-37.

Yamazaki H, Okayama A, Imai N, Guengerich FP, Shimizu M. Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica 2006; 36:1201-9.

Yamazaki H, Shimada T. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys 1997; 346:161-9.

Yamazaki H, Shimada T. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos 1998; 26:1053-7.

Yamazaki H, Shibata A, Suzuki M et al. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 1999; 27:1260-6.

Yamazaki H, Suzuki M, Tane K, Shimada N, Nakajima M, Yokoi T. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica 2000; 30:61-70.

Yamazaki H, Urano T, Hiroki S, Shimada T. Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes. J Toxicol Sci 1996; 21:215-26.

Yamazaki K, Suzuki M, Itoh T et al. Structural basis of species differences between human and experimental animal CYP1A1s in metabolism of 3,3’,4,4’,5-pentachlorobiphenyl. J Biochem 2011; 149:487-94.

Yamazaki M, Li B, Louie SW et al. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 2005; 35:737-53.

Yamazaki R, Nishiyama Y, Furuta T et al. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther 2011; 10:1252-63.

Yamazaki S, Toth LN, Black ML, Duncan JN. Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans. Drug Metab Dispos 2004; 32:398-404.

Yamazaki Y, Fujita K, Nakayama K et al. Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens. Mutat Res 2004; 562:151-62.

Yamreudeewong W, DeBisschop M, Martin LG, Lower DL. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003; 26:421-38.

Yan F, Wang XM, Liu ZC, Pan C, Yuan SB, Ma QM. JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int 2010; 9:287-95.

Yan G, Liu W, Dai ZX et al. Study of a new zebrafish mutant defective in primitive myelopoiesis. Nan Fang Yi Ke Da Xue Xue Bao 2011; 31:755-60.

Yan JB, Xu HP, Xiong C et al. Rapid and reliable detection of glucose-6-phosphate dehydrogenase (G6PD) gene mutations in Han Chinese using high-resolution melting analysis. J Mol Diagn 2010; 12:305-11.

Yan L, Huo P, Debenham JS et al. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity. J Med Chem 2010; 53:4028-37.

Yan L, Otterness DM, Weinshilboum RM. Human nicotinamide N-methyltransferase pharmacogenetics: gene sequence analysis and promoter characterization. Pharmacogenetics 1999; 9:307-16.

Yan SB, Nelson DR. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med 2004; 32:239-46.

Yan SD, Chen M, Li Q et al. The value of combining CYP2C19*2 polymorphism with classic risk factors in prediction of clinical prognosis in acute coronary syndrome patients. Cardiology 2011; 119:15-20.

Yan SL, Wu ST, Yin MC, Chen HT, Chen HC. Protective effects from carnosine and histidine on acetaminophen-induced liver injury. J Food Sci 2009; 74:259-65.

Yan W, Zhang T, Cheng J, Zhou X, Qu X, Hu H. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride. Pharmacology 2010; 86:306-12.

Yan X, Takahara M, Xie L et al. Arginine metabolism in soft tissue sarcoma. J Dermatol Sci 2011; 61:211-5.

Yan Y, Yang JY, Mou YH, Wang LH, Zhang H, Wu CF. Possible metabolic pathways of ethanol responsible for oxidative DNA damage in human peripheral lymphocytes. Alcohol Clin Exp Res 2011; 35:1-9.

Yan Z, Caldwell GW, Wu WN et al. In vitro identification of metabolic pathways and cytochrome P450 enzymes involved in the metabolism of etoperidone. Xenobiotica 2002; 32:949-62.

Yanagiba Y, Ito Y, Kamijima M, Gonzalez FJ, Nakajima T. Octachlorostyrene induces cytochrome P450, UDP-glucuronosyltransferase, and sulfotransferase via the aryl hydrocarbon receptor and constitutive androstane receptor. Toxicol Sci 2009; 111:19-26.

Yanagimachi M, Naruto T, Tanoshima R et al. Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation. Clin Transplant 2010; 24:855-61.

Yanagisawa R, Katsuyama Y, Shigemura T et al. Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. Bone Marrow Transplant 2011; 46:90-7.

Yanamandra K, Napper D, Pramanik A, Bocchini JA Jr, Dhanireddy R. Endothelial nitric oxide synthase genotypes in the etiology of retinopathy of prematurity in premature infants. Ophthalmic Genet 2010; 31:173-7.

Yanase K, Tsukahara S, Mitsuhashi J, Sugimoto Y. Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development. Cancer Lett 2006; 234:73-80.

Yancey SW, Klotsman M, Ortega HG, Edwards LD, Anderson WH. Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms. Curr Med Res Opin 2009; 25:1011-8.

Yancopoulou D, Crowther RA, Charkrabarti L, Gydesen S, Brown JM, Spillantini MG. Tau protein in frontotemporal dementia linked to chromosome 3 (FTD-3). J Neuropathol Exp Neurol 2003; 62:878-82.

Yang AK, He SM, Liu L, Liu JP, Wei MQ, Zhou SF. Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Curr Med Chem 2010; 17:1635-78.

Yang AK, Zhou ZW, Wei MQ, Liu JP, Zhou SF. Modulators of multidrug resistance associated proteins in the management of anticancer and antimicrobial drug resistance and the treatment of inflammatory diseases. Curr Top Med Chem 2010; 10:1732-56.

Yang CQ, Chan KY, Ngan HY et al. Single nucleotide polymorphisms of follicle-stimulating hormone receptor are associated with ovarian cancer susceptibility. Carcinogenesis 2006; 27:1502-6.

Yang CY, Chao PD, Hou YC, Tsai SY, Wen KC, Hsiu SL. Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats. Food Chem Toxicol 2006; 44:1572-8.

Yang D, Wang X, Chen YT, Deng R, Yan B. Pyrethroid insecticides: isoform-dependent hydrolysis, induction of cytochrome P450 3A4 and evidence on the involvement of the pregnane X receptor. Toxicol Appl Pharmacol 2009; 237:49-58.

Yang GZ, Yu HR, Yuan Y, Zhou QX, Liu YJ. RNA interference-mediated silencing of cytochrome P450 3A4 gene in CHL-3A4 cells. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28:2227-9.

Yang GZ, Yuan Y, Zhou QX, Yang JQ, Liu YJ. Effect of ketoconazole on the activity of CYP4503A4 and CYP450 1A2 of hepatic microsomes in healthy adults. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28:1634-5, 1639.

Yang H, Francis SC, Sellers K et al. Hypertension-linked decrease in the expression of brain gamma-adducin. Circ Res 2002; 91:633-9.

Yang H, Nie Y, Li Y, Wan YJ. Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Exp Biol Med 2010; 235:32-9.

Yang H, Zhou Y, Zhou Z et al. A novel polymorphism rs1329149 of CYP2E1 and a known polymorphism rs671 of ALDH2 of alcohol metabolizing enzymes are associated with colorectal cancer in a southwestern Chinese population. Cancer Epidemiol Biomarkers Prev 2009; 18:2522-7.

Yang HP, Gonzalez Bosquet J, Li Q et al. Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. Carcinogenesis 2010; 31:827-33.

Yang HY, Lee QP, Rettie AE, Juchau MR. Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Mol Pharmacol 1994; 46:922-8.

Yang HY, Lin HS, Chao JC, Chien YW, Peng HC, Chen JR. Effects of soy protein on alcoholic liver disease in rats undergoing ethanol withdrawal. J Nutr Biochem 2011. doi:10. 1016/j. jnutbio. 2011. 03. 016.

Yang J, He MM, Niu W et al. Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes. Br J Clin Pharmacol 2011. doi:10. 1111/j. 1365-2125. 2011. 04076. x.

Yang J, Ji Y, Mehta P, Bates KA, Sun Y, Wisniewski T. Blocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. J Alzheimers Dis 2011; 24:269-85.

Yang J, Kamide K, Kokubo Y et al. Associations of hypertension and its complications with variations in the xanthine dehydrogenase gene. Hypertens Res 2008; 31:931-40.

Yang J, Yan B. Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor. Toxicol Sci 2007; 95:13-22.

Yang JC, Wang HL, Chern HD et al. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. Pharmacotherapy 2011; 31:227-38.

Yang JC, Yang YF, Uang YS, Lin CJ, Wang TH. Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. Br J Clin Pharmacol 2009; 67:503-10.

Yang JD, Feng GY, Zhang J et al. Apolipoprotein E –491 promoter polymorphism is a independent risk factor for Alzheimer’s disease in the Chinese population. Neurosci Lett 2003; 350:25-8.

Yang JD, Shang HT, Wei H, Yang WS, Liu X. Expression of CYP3A29 mRNA in Chinese experimental miniature pig’s livers quantitated with real-time reverse transcription polymerase chain reaction. Yi Chuan 2007; 29:575-80.

Yang JH, Kondratyuk TP, Jermihov KC et al. Bioactive compounds from the fern Lepisorus contortus. J Nat Prod 2011; 74:129-36.

Yang JH, Kondratyuk TP, Marler LE et al. Isolation and evaluation of kaempferol glycosides from the fern Neocheiropteris palmatopedata. Phytochemistry 2010; 71:641-7.

Yang JJ, Milton MN, Yu S et al. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metab Lett 2010; 4:201-12.

Yang JK, Zhou JB, Xin Z et al. Interactions among related genes of renin-angiotensin system associated with type 2 diabetes. Diabetes Care 2010; 33:2271-3.

Yang JP, Liu Y, Zhong W, Yu D, Wen LJ, Jin CS. Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma. Chin Med J 2011; 124:1055-60.

Yang JY, Ha SA, Yang YS, Kim JW. p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance. BMC Cancer 2010; 10:388.

Yang K, Koh KH, Jeong H. Induction of CYP2B6 and CYP3A4 expression by 1-aminobenzotriazole (ABT) in human hepatocytes. Drug Metab Lett 2010; 4:129-33.

Yang K, Zhang G, Mei J, Chen D, Wu M. Screening and analysis of pathogenic genes during DMBA-induced buccal mucosa carcinogenesis in golden hamsters. Oncol Rep 2010; 23:1619-24.

Yang L, Ge W, Yu F, Zhu H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis. Thromb Res 2010; 125:159-66.

Yang L, Wang LJ, Shi GL et al. Analysis of HLA-A, HLA-B and HLA-DRB1 alleles in Chinese patients with lung cancer. Genet Mol Res 2010; 9:750-5.

Yang L, Wu D, Wang X, Cederbaum AI. Depletion of cytosolic or mitochondrial thioredoxin increases CYP2E1-induced oxidative stress via an ASK-1-JNK1 pathway in HepG2 cells. Free Radic Biol Med 2011; 51:185-96.

Yang LJ, Fan L, Liu ZQ et al. Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes. Eur J Clin Pharmacol 2009; 65:601-8.

Yang LQ, Li SJ, Cao YF et al. Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J Gastroenterol 2003; 9:359-63.

Yang LQ, Yu WF, Cao YF, Gong B, Chang Q, Yang GS. Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes. World J Gastroenterol 2003; 9:1959-62.

Yang M, Coles BF, Delongchamp R, Lang NP, Kadlubar FF. Effects of the ADH3, CYP2E1, and GSTP1 genetic polymorphisms on their expressions in Caucasian lung tissue. Lung Cancer 2002; 38:15-21

Yang M, Huang Q, Wu J et al. Effects of UCP2 -866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes. Br J Clin Pharmacol 2009; 68:14-22.

Yang M, Zhang R, Yan M, Ye Z, Liang W, Luo Z. Detection and characterization of side population in Ewing’s sarcoma SK-ES-1 cells in vitro. Biochem Biophys Res Commun 2010; 391:1062-6.

Yang MH, Zhao MY, He YL et al. Interaction of WAVE1 and genes involved in multiple drug resistance in children with acute myeloblastic leukemia. Zhonghua Er Ke Za Zhi 2010; 48:175-9.

Yang MH, Zhao MY, Wang Z et al. WAVE1 regulates P-glycoprotein expression via Ezrin in leukemia cells. Leuk Lymphoma 2011; 52:298-309.

Yang P, Ebbert JO, Sun Z, Weinshilboum RM. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol 2006; 24:1761-9.

Yang P, Kanki H, Drolet B et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002; 105:1943-8.

Yang Q, Kathiresan S, Lin JP, Tofler GH, O’Donnell CJ. Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study. BMC Med Genet 2007; 8 Suppl 1:12.

Yang Q, Köttgen A, Dehghan A et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 2010; 3:523-30.

Yang SH, Cheng PH, Banta H et al. Towards a transgenic model of Huntington’s disease in a non-human primate. Nature 2008; 453:921-4.

Yang SH, Cho YA, Choi JS. Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats. Acta Pharmacol Sin 2011; 32:967-72.

Yang SH, Huang CJ, Chang SC, Lin JK. Association of C-reactive protein gene polymorphisms and colorectal cancer. Ann Surg Oncol 2011; 18:1907-15.

Yang SS, Lo YF, Yu IS et al. Generation and analysis of the thiazide-sensitive Na+ -Cl- cotransporter (Ncc/Slc12a3) Ser707X knockin mouse as a model of Gitelman syndrome. Hum Mutat 2010; 31:1304-15.

Yang SY, Yang TY, Chen KC et al. EGFR L858R mutation and polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patients. Clin Cancer Res 2011; 17:2149-58.

Yang T, McBride BF, Leake BF, Kim RB, Roden DM. Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. Br J Pharmacol 2010; 161:1023-33.

Yang W, Dunlap J, Andrews R, Wetzel R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Molec Genet 2002; 11:2905-17.

Yang WS, Yang YC, Chen CL et al. Adiponectin SNP276 is associated with obesity, the metabolic syndrome, and diabetes in the elderly. Am J Clin Nutr 2007; 86:509-13.

Yang X, Chen SQ, Liu M. Association of the CYP19 gene polymorphism with genetic susceptibility to endometriosis. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2010; 27:692-6.

Yang X, Liao M, Yang Z, Guo J, Gao Q. Effect of Panax notoginseng on genes expression of CYP and GST in lung tissues of rats. Zhongguo Zhong Yao Za Zhi 2009; 34:2236-40.

Yang X, Liao M, Yang Z, Guo J, Gao Q. Effect of Panax notoginseng on genes expression of CYP and GST in liver tissues of rats. Zhongguo Zhong Yao Za Zhi 2009; 34:2390-3.

Yang X, Liu Y, Zong Z, Tian D. The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells. Biomed Pharmacother 2010; 64:58-62.

Yang X, Morris ME. Pharmacokinetics and biliary excretion of mitoxantrone in rats. J Pharm Sci 2010; 99:2502-10.

Yang X, Pfeiffer RM, Goldstein AM. Influence of glutathione-S-transferase (GSTM1, GSTP1, GSTT1) and cytochrome p450 (CYP1A1, CYP2D6) polymorphisms on numbers of basal cell carcinomas (BCCs) in families with the naevoid basal cell carcinoma syndrome. J Med Genet 2006; 43:16.

Yang XG, Jiang C. Ligustrazine as a salvage agent for patients with relapsed or refractory non-Hodgkin’s lymphoma. Chin Med J 2010; 123:3206-11.

Yang XR, Xu Y, Yu B et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 2010; 59:953-62.

Yang Y, Dahly-Vernon AJ, Blomme EA et al. Liver transcriptomic changes associated with ritonavir-induced hyperlipidemia in sensitive and resistant strains of rats. Vet J 2010; 185:75-82.

Yang Y, Lingling S, Ying J et al. Association study between the IL4, IL13, IRF1 and UGRP1 genes in chromosomal 5q31 region and Chinese Graves’ disease. J Hum Genet 2005; 50:574-82.

Yang Y, Luo C, Feng R, Bi S. The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2011; 137:947-52.

Yang Y, Mo W, Zhang JT. Role of transmembrane segment 5 and extracellular loop 3 in the homodimerization of human ABCC1. Biochemistry 2010; 49:10854-61.

Yang Y, Sun R, Yang H, Zheng F, Gong F. -308 G>A of TNF-α gene promoter decreases the risk of multiple sclerosis: a meta-analysis. Mult Scler 2011; 17:658-65.

Yang Y, Wu K, Yuan H, Yu M. Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol. J Ocul Pharmacol Ther 2009; 25:163-71.

Yang Y, Zhai XD, Gao LB, Li SL, Wang Z, Chen GD. Genetic polymorphisms of DNA repair gene XRCC1 and risk of uterine leiomyoma. Mol Cell Biochem 2010; 338:143-7.

Yang YH, Liu CK. Angiotensin-converting enzyme gene in Alzheimer’s disease. Tohoku J Exp Med 2008; 215:295-8.

Yang YH, Miranda CL, Henderson MC, Wang-Buhler JL, Buhler DR. Heterologous expression of CYP2K1 and identification of the expressed protein (BV-CYP2K1) as lauric acid (omega-1)-hydroxylase and aflatoxin B1 exo-epoxidase. Drug Metab Dispos 2000; 28:1279-83.

Yang YN, Wang XL, Ma YT et al. Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. Clin Appl Thromb Hemost 2010; 16:579-83.

Yang YY, Lin HC, Lin MW et al. Identification of diuretic non-responders with poor long-term clinical outcomes: a 1-year follow-up of 176 non-azotaemic cirrhotic patients with moderate ascites. Clin Sci 2011; 121:509-21.

Yang Z, Wu D, Bui T, Ho RJ. A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. J Pharmacol Exp Ther 2008; 327:474-81.

Yang ZF, Cui HW, Hasi T, Jia SQ, Gong ML, Su XL. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China. Genet Mol Res 2010; 9:1844-51.

Yanni SB, Annaert PP, Augustijns P et al. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos 2008; 36:1119-25.

Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK Jr, Thakker DR. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos 2010; 38:25-31.

Yanni SB, Augustijns PF, Benjamin DK Jr, Brouwer KL, Thakker DR, Annaert PP. In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats. Drug Metab Dispos 2010; 38:1848-56.

Yanpallewar SU, Fernandes K, Marathe SV et al. Alpha2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment. J Neurosci 2010; 30:1096-109.

Yantsevich AV, Gilep AA, Usanov SA. Electron transfer properties and catalytic competence of cytochrome b5 in the fusion protein Hmwb5-EGFP in reactions catalyzed by cytochrome P450 3A4. Biochemistry 2009; 74:862-73.

Yanxiao C, Ruijuan X, Jin Y et al. Organic anion and cation transporters are possibly involved in renal excretion of entecavir in rats. Life Sci 2011; 89:1-6.

Yao D, Ding S, Burchell B, Wolf CR, Friedberg T. Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther 2000; 294:387-95.

Yao H, McCullough CR, Costache AD, Pullela PK, Sem DS. Structural evidence for a functionally relevant second camphor binding site in P450cam: model for substrate entry into a P450 active site. Proteins 2007; 69:125-38.

Yao HT, Chang YW, Lan SJ, Chen CT, Hsu JT, Yeh TK. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci 2006; 79:2432-40.

Yao HT, Lin JH, Chiang MT, Chiang W, Luo MN, Lii CK. Suppressive effect of the ethanolic extract of adlay bran on cytochrome P-450 enzymes in rat liver and lungs. J Agric Food Chem 2011; 59:4306-14.

Yao L, Fang F, Wu Q, Zhong Y, Yu L. No association between CYP1B1 Val432Leu polymorphism and breast cancer risk: a meta-analysis involving 40,303 subjects. Breast Cancer Res Treat 2010; 122:237-42.

Yao L, Fang F, Zhong Y, Yu L. The association between two polymorphisms of eNOS and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010; 124:223-7.

Yao M, Srinivas NR. Bioanalytical methods for the determination of itraconazole and hydroxyitraconazole: overview from clinical pharmacology, pharmacokinetic, pharmacodynamic and metabolism perspectives. Biomed Chromatogr 2009; 23:677-91.

Yao M, Zhu M, Sinz MW et al. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis. J Pharm Biomed Anal 2007; 44:211-23.

Yao P, Hao L, Nussler N et al. The protective role of HO-1 and its generated products (CO, bilirubin, and Fe) in ethanol-induced human hepatocyte damage. Am J Physiol Gastrointest Liver Physiol 2009; 296:1318-23.

Yao R, Yasuoka A, Kamei A et al. Dietary flavonoids activate the constitutive androstane receptor (CAR). J Agric Food Chem 2010; 58:2168-73.

Yao S, Barlow WE, Albain KS et al. Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res 2010; 16:6169-76.

Yao S, Xu B, Li Q et al. Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer. Endocr J 2011; 58:509-16.

Yao TW, Zhou Q, Zeng S. Stereoselective determination of propafenone enantiomers in transgenic Chinese hamster CHL cells expressing human cytochrome P450. Biomed Chromatogr 2000; 14:498-501.

Yao X, Dai C, Fredriksson K et al. 5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma. J Immunol 2011; 186:576-83.

Yao YM, Cao W, Cao YJ et al. Effect of sinomenine on human cytochrome P450 activity. Clin Chim Acta 2007; 379:113-8.

Yap CW, Chen YZ. Prediction of cytochrome P450 3A4, 2D6, and 2C9 inhibitors and substrates by using support vector machines. J Chem Inf Model 2005; 45:982-92.

Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 2008; 30:1385-407.

Yap KY, See CS, Chan A. Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer. Recent Pat Food Nutr Agric 2010; 2:12-55.

Yardley DA. Proactive management of adverse events maintains the clinical benefit of ixabepilone. Oncologist 2009; 14:448-55.

Yardley DA, Burris HA 3rd, Clark BL et al. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium. Clin Breast Cancer 2011; 11:146-52.

Yasar U, Annas A, Svensson JO, Lazorova L, Artursson P, Al-Shurbaji A. Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica 2005; 35:785-96.

Yasar U, Eliasson E, Forslund-Bergengren C et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 2001; 57:729-35.

Yasar U, Forslund-Bergengren C, Tybring G et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002; 71:89-98.

Yasar U, Sain-Guven G, Yardimci Y, Kilicarslan A, Babaoglu MO, Bozkurt A. Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients. Basic Clin Pharmacol Toxicol 2011; 109:73-7.

Yasar U, Tybring G, Hidestrand M et al. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 2001; 29:1051-6.

Yasovanthi J, Venkata Karunakar K, Sri Manjari K et al. Association of vitamin D receptor gene polymorphisms with BMD and their effect on 1, 25-dihydroxy vitamin D3 levels in pre- and postmenopausal South Indian women from Andhra Pradesh. Clin Chim Acta 2011; 412:541-4.

Yasu T, Ikee R, Miyasaka Y, Chubachi H, Saito S. Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study. Yakugaku Zasshi 2010; 130:1743-50.

Yasuda H, Kamide K, Takiuchi S et al. Association of single nucleotide polymorphisms in endothelin family genes with the progression of atherosclerosis in patients with essential hypertension. J Hum Hypertens 2007; 21:883-92.

Yasuda K, Ikushiro S, Kamakura M, Munetsuna E, Ohta M, Sakaki T. Sequential metabolism of sesamin by cytochrome P450 and UDP-glucuronosyltransferase in human liver. Drug Metab Dispos 2011; 39:1538-45.

Yasuda K, Ikushiro S, Kamakura M, Ohta M, Sakaki T. Metabolism of sesamin by cytochrome P450 in human liver microsomes. Drug Metab Dispos 2010; 38:2117-23.

Yasuda K, Miyake K, Horikawa Y et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 2008; 40:1092-7.

Yasuda K, Ranade A, Venkataramanan R et al. A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos 2008; 36:1689-97.

Yasuda M, Kawamata T, Komure O et al. A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration. Neurology 1999; 53:864-8.

Yasuda M, Yokoyama K, Nakayasu T et al. A Japanese patient with frontotemporal dementia and parkinsonism by a tau P301S mutations. Neurology 2000; 55:1224-7.

Yasuda SU, Zannikos P, Young AE, Fried KM, Wainer IW, Woosley RL. The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol 2002; 53:519-25.

Yasuda Y, Kudo T, Katayama T et al. FAD-linked presenilin-1 mutants impede translation regulation under ER stress. Biochem Biophys Res Commun 2002; 296:313-8.

Yasui H, Deo K, Ogura Y et al. Evidence for singlet oxygen involvement in rat and human cytochrome P450-dependent substrate oxidations. Drug Metab Pharmacokinet 2002; 17:416-26.

Yasui N, Kondo T, Furukori H et al. Effects of repeated ingestion of grapefruit juice on the single and multiple oral-dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology 2000; 150:185-90.

Yasui N, Kondo T, Otani K et al. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology 1998; 139:269-73.

Yasui N, Kondo T, Otani K et al. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. J Clin Psychopharmacol 1999; 19:149-54.

Yasui N, Kondo T, Suzuki A et al. Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice. Int Clin Psychopharmacol 1999; 14:113-8.

Yasui N, Otani K, Kaneko S et al. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 1995; 17:333-5.

Yasui N, Otani K, Kaneko S et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 1996; 59:514-9.

Yasui N, Otani K, Ohkubo T et al. Single-dose pharmacokinetics and pharmacodynamics of oral triazolam in relation to cytochrome P4502C19 (CYP2C19) activity. Ther Drug Monit 1997; 19:371-4.

Yasui N, Tybring G, Otani K et al. Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. Pharmacogenetics 1997; 7:369-74.

Yasui-Furukori N, Hidestrand M, Spina E, Facciolá G, Scordo MG, Tybring G. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001; 29:1263-8.

Yasui-Furukori N, Kondo T, Kubota T et al. No correlations between the urinary ratio of 6beta-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam. Eur J Clin Pharmacol 2001; 57:285-8.

Yasui-Furukori N, Kondo T, Mihara K et al. Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone. J Clin Pharmacol 2002; 42:1083-8.

Yasui-Furukori N, Mihara K, Takahata T et al. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol 2004; 57:569-75.

Yasui-Furukori N, Saito M, Inoue Y et al. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Eur J Clin Pharmacol 2007; 63:51-6.

Yasui-Furukori N, Saito M, Tsuchimine S et al. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1491-5.

Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol 2004; 44:1223-9.

Yasukochi Y, Satta Y. Evolution of the CYP2D gene cluster in humans and four non-human primates. Genes Genet Syst 2011; 86:109-16.

Yasunaga S, Kimura A, Hamaguchi K, Ronningen KS, Sasazuki T. Different contribution of HLA-DR and -DQ genes in susceptibility and resistance to insulin-dependent diabetes mellitus (IDDM). Tissue Antigens 1996; 47:37-48.

Yasunami M, Kikuchi I, Sarapata D, Yoshida A. The human class I alcohol dehydrogenase gene cluster: three genes are tandemly organized in an 80-kb-long segment of the genome. Genomics 1990; 7:152-8.

Yasunami Y, Hara H, Iwamura T, Kataoka T, Adachi T. C-jun N-terminal kinase modulates 1,25-dihydroxyvitamin D3-induced cytochrome P450 3A4 gene expression. Drug Metab Dispos 2004; 32:685-8.

Yasuno F, Suhara T, Ichimiya T, Takano A, Ando T, Okubo Y. Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry 2004; 55:439-44.

Yates CR, Zhang W, Song P et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003; 43:555-64.

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. Haematologica 2004; 89:1172-8.

Yde CW, Clausen MP, Bennetzen MV, Lykkesfeldt AE, Mouritsen OG, Guerra B. The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells. Anticancer Drugs 2009; 20:723-35.

Ye CG, Wu WK, Yeung JH et al. Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression. Cancer Lett 2011; 304:90-6.

Ye D, Lammers B, Zhao Y, Meurs I, van Berkel TJ, van Eck M. ATP-binding cassette transporters A1 and G1, HDL metabolism, cholesterol efflux, and inflammation: important targets for the treatment of atherosclerosis. Curr Drug Targets 2011; 12:647-60.

Ye D, Meurs I, Ohigashi M et al. Macrophage ABCA5 deficiency influences cellular cholesterol efflux and increases susceptibility to atherosclerosis in female LDLr knockout mice. Biochem Biophys Res Commun 2010; 395:387-94.

Ye L, Tang L, Gong Y et al. Characterization of metabolites and human P450 isoforms involved in the microsomal metabolism of mesaconitine. Xenobiotica 2011; 41:46-58.

Ye L, Wang T, Yang C et al. Microsomal cytochrome P450-mediated metabolism of hypaconitine, an active and highly toxic constituent derived from Aconitum species. Toxicol Lett 2011; 204:81-91.

Ye S, Dhillon S, Seear R et al. Epistatic interaction between variations in the angiotensin I converting enzyme and angiotensin II type 1 receptor genes in relation to extent of coronary atherosclerosis. Heart 2003; 89:1195-9.

Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996; 271:13055-60.

Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995; 73:209-15.

Ye X, Li W, Yan Y et al. Effects of cytochrome P4503A inducer dexamethasone on the metabolism and toxicity of triptolide in rat. Toxicol Lett 2010; 192:212-20.

Ye X, Peng T, Liu T et al. Association between aldehyde dehydrogenase-2/cytochrome P450 2E1 genetic polymorphism and habit of alcohol drinking and the susceptibility of hepatocellular carcinoma. Wei Sheng Yan Jiu 2010; 39:42-5.

Ye XW, Xiao M, Ye J et al. The polymorphism -2548G/A in leptin and severity of chronic obstructive pulmonary disease. Int J Immunogenet 2011; 38:45-50.

Ye Y, Lukinova N, Fortini ME. Neurogenic phenotypes and altered Notch processing in Drosophila presenilin mutants. Nature 1999, 398:525-9.

Ye Y, Yang H, Grossman HB, Dinney C, Wu X, Gu J. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer 2008; 112:2467-74.

Ye YM, Kang YM, Kim SH et al. Relationship between neurokinin 2 receptor gene polymorphisms and serum vascular endothelial growth factor levels in patients with toluene diisocyanate-induced asthma. Clin Exp Allergy 2006; 36:1153-60.

Ye YM, Lee HY, Kim SH et al. Pharmacogenetic study of the effects of NK2R G231E G>A and TBX21 H33Q C>G polymorphisms on asthma control with inhaled corticosteroid treatment. J Clin Pharm Ther 2009; 34:693-701.

Ye Z, Liu Z, Henderson A et al. Increased CYP4B1 mRNA is associated with the inhibition of dextran sulfate sodium-induced colitis by caffeic acid in mice. Exp Biol Med 2009; 234:605-16.

Ye ZW, Camus S, Augustijns P, Annaert P. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos 2010; 31:178-88.

Yee LJ, Perez KA, Tang J, van Leeuwen DJ, Kaslow RA. Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. J Infect Dis 2003; 187:1264-71.

Yee SW, Shima JE, Hesselson S et al. Identification and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2). J Pharmacol Exp Ther 2009; 328:699-707.

Yeh CC, Sung FC, Tang R, Chang-Chieh CR, Hsieh LL. Polymorphisms of cytochrome P450 1A2 and N-acetyltransferase genes, meat consumption, and risk of colorectal cancer. Dis Colon Rectum 2009; 52:104-11.

Yeh S, Miyamoto H, Shima H, Chang C. From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc Natl Acad Sci U S A 1998; 95:5527-32.

Yeh SH, Chiu CM, Chen CL et al. Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma. Int J Cancer 2007; 120:1610-7.

Yellon SM, Ebner CA, Sugimoto Y. Parturition and recruitment of macrophages in cervix of mice lacking the prostaglandin F receptor. Biol Reprod 2008; 78:438-44.

Yen JH, Chen CJ, Tsai WC et al. HLA-DQA1 genotyping in patients with rheumatoid arthritis in Taiwan. Kaohsiung J Med Sci 2001; 17:183-9.

Yen LC, Uen YH, Wu DC et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg 2010; 251:254-60.

Yengi LG, Xiang Q, Pan J et al. Quantitation of cytochrome P450 mRNA levels in human skin. Anal Biochem 2003; 316:103-10.

Yeni P, Lamarca A, Berger D et al. Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136). HIV Med 2009; 10:116-24.

Yen-Revollo JL, van Booven DJ, Peters EJ et al. Influence of ethnicity on pharmacogenetic variation in the Ghanaian population. Pharmacogenomics J 2009; 9:373-9.

Yenugonda VM, Deb TB, Grindrod SC et al. Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells. Bioorg Med Chem 2011; 19:2714-25.

Yeo CW, Lee SJ, Lee SS et al. Discovery of a novel allelic variant of CYP2C8, CYP2C8*11, in Asian populations and its clinical effect on the rosiglitazone disposition in vivo. Drug Metab Dispos 2011; 39:711-6.

Yeo GS, Connie Hung CC, Rochford J et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 2004; 7:1187-9.

Yeo KP, Lowe SL, Lim MT, Voelker JR, Burkey JL, Wise SD. Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction. Br J Clin Pharmacol 2006; 61:200-10.

Yeo KR, Yeo WW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 2001; 51:461-70.

Yeoh AE, Lu Y, Chan JY et al. Genetic susceptibility to childhood acute lymphoblastic leukemia shows protection in Malay boys: results from the Malaysia-Singapore ALL Study Group. Leuk Res 2010; 34:276-83.

Yeoh EJ, Ross ME, Shurtleff SA et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1:133-43.

Yeum CH, Choi JS. Effect of naringin pretreatment on bioavailability of verapamil in rabbits. Arch Pharm Res 2006; 29:102-7.

Yeung CK, Rettie AE. Benzydamine N-oxygenation as a measure of flavin-containing monooxygenase activity. Methods Mol Biol 2006; 320:157-62.

Yeung EY, Sueyoshi T, Negishi M, Chang TK. Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab Dispos 2008; 36:2270-6.

Yeung JH, Or PM. Polysaccharide peptides from Coriolus versicolor competitively inhibit tolbutamide 4-hydroxylation in specific human CYP2C9 isoform and pooled human liver microsomes. Phytomedicine 2011; 18:1170-5.

Yeung JH, Wong JK, Park BK. Development of a screening method for anti-6 beta-hydroxycortisol antibody using an enzyme-linked immunosorbent assay (ELISA) and its applications. Methods Find Exp Clin Pharmacol 1997; 19:79-86.

Yi GW, Zeng QT, Mao XB et al. Overexpression of CXCL16 promotes a vulnerable plaque phenotype in Apolipoprotein E-Knockout Mice. Cytokine 2011; 53:320-6.

Yi JF, Li YM, Liu T et al. Mn-SOD and CuZn-SOD polymorphisms and interactions with risk factors in gastric cancer. World J Gastroenterol 2010; 16:4738-46.

Yi L, Wang JW, Zhao RG, Tuo HZ, Feng ZJ, Wang DX. Fluvastatin’s effect on atherogenesis in apolipoprotein-E knockout mice infected by cytomegalovirus. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2010; 24:433-5.

Yi P, Hadden C, Kulanthaivel P et al. Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans. Drug Metab Dispos 2010; 38:554-65.

Yi S, Cho JY, Lim KS et al. Effects of Angelicae tenuissima radix, Angelicae dahuricae radix and Scutellariae radix extracts on cytochrome P450 activities in healthy volunteers. Basic Clin Pharmacol Toxicol 2009; 105:249-56.

Yildirim Yaroğlu H, Calikoğlu M, Tamer Gümüş L. CYP2C19 gene polymorphism may be a risk factor for bronchial asthma. Med Princ Pract 2011; 20:39-42.

Yilmaz A, Kaya MG, Merdanoglu U, Ergun MA, Cengel A, Menevse S. Association of beta-1 and beta-2 adrenergic receptor gene polymorphisms with myocardial infarction. J Clin Lab Anal 2009; 23:237-43.

Yilmaz MB, Wolfe A, Zhao H, Brooks DC, Bulun SE. Aromatase promoter I. f is regulated by progesterone receptor in mouse hypothalamic neuronal cell lines. J Mol Endocrinol 2011; 47:69-80.

Yim H, Na K. Polycationic nanodrug covered with hyaluronic acid for treatment of P-glycoprotein overexpressing cancer cells. Biomacromolecules 2010; 11:2387-93.

Yin B, Yang Y, Zhao Z et al. Arachidonate 12-lipoxygenase may serve as a potential marker and therapeutic target for prostate cancer stem cells. Int J Oncol 2011; 38:1041-6.

Yin G, Kono S, Toyomura K et al. Alcohol dehydrogenase and aldehyde dehydrogenase polymorphisms and colorectal cancer: the Fukuoka Colorectal Cancer Study. Cancer Sci 2007; 98:1248-53.

Yin H, Borghi MO, Delgado-Vega AM, Tincani A, Meroni PL, Alarcón-Riquelme ME. Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum 2009; 60:2468-71.

Yin J, Sakamoto K, Zhang H et al. Transforming growth factor-beta1 upregulates keratan sulfate and chondroitin sulfate biosynthesis in microglias after brain injury. Brain Res 2009; 1263:10-22.

Yin JY, Huang Q, Yang Y et al. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics 2009; 19:206-16.

Yin KJ, Cirrito JR, Yan P et al. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J Neurosci 2006; 26:10939-48.

Yin OQ, Gallagher N, Fischer D et al. Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects. Clin Drug Investig 2011; 31:169-79.

Yin OQ, Shi XJ, Tomlinson B, Chow MS. Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. Drug Metab Dispos 2005; 33:1283-7.

Yin OQ, Tomlinson B, Chow MS. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin Pharmacol Ther 2005; 78:370-7.

Yin OQ, Tomlinson B, Chow MS. CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition. J Clin Pharmacol 2010; 50:1136-41.

Yin SJ, Bosron WF, Li TK et al. Polymorphism of human liver alcohol dehydrogenase: identification of ADH(2)2-1 and ADH(2)2-2 phenotypes in the Japanese by isoelectric focusing. Biochem Genet 1984; 22:169-80.

Yin SJ, Ni YB, Wang SM, Wang X, Lou YQ, Zhang GL. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Ther 2011. doi:10. 1111/j. 1365-2710. 2011. 01298. x.

Yin T, Maekawa K, Kamide K et al. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 2008; 31:1549-57.

Yin W, Mitra K, Stearns RA, Baillie TA, Kumar S. Conversion of the 2,2,6,6-tetramethylpiperidine moiety to a 2,2-dimethylpyrrolidine by cytochrome P450: evidence for a mechanism involving nitroxide radicals and heme iron. Biochemistry 2004; 43:5455-66.

Yin X, Hou T, Liu Y et al. Association of Toll-like receptor 4 gene polymorphism and expression with urinary tract infection types in adults. PLoS One 2010. doi:10. 1371/journal. pone. 0014223.

Yin Z, Xiong C, Wang Y, Zhou X, Yan SK. Investigation of the relationship between apolipoprotein E gene polymorphisms and hepatitis B virus infection in northern China. Clin Chem Lab Med 2010; 48:1803-7.

Yip-Schneider MT, Doyle CJ, McKillop IH et al. Alcohol induces liver neoplasia in a novel alcohol-preferring rat model. Alcohol Clin Exp Res 2011. doi:10. 1111/j. 1530-0277. 2011. 01568. x.

Yiu CC, Sasano H, Ono K, Chow LW. Changes in protein expression after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance. Expert Opin Investig Drugs 2010; 19 Suppl 1:79-89.

Yiu WF, Kwan PL, Wong CY et al. Attenuation of fatty liver and prevention of hypercholesterolemia by extract of Curcuma longa through regulating the expression of CYP7A1, LDL-receptor, HO-1, and HMG-CoA reductase. J Food Sci 2011; 76:80-9.

Yogalakshmi B, Viswanathan P, Anuradha CV. Investigation of antioxidant, anti-inflammatory and DNA-protective properties of eugenol in thioacetamide-induced liver injury in rats. Toxicology 2010; 268:204-12.

Yoh K, Ishii G, Yokose T et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 2004; 10:1691-7.

Yokohira M, Arnold LL, Pennington KL et al. Effect of sodium arsenite dose administered in the drinking water on the urinary bladder epithelium of female arsenic (+3oxidation state) methyltransferase knockout mice. Toxicol Sci 2011; 121:257-66.

Yokoi T. Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children. J Toxicol Sci 2009; 34 Suppl 2:307-12.

Yokoi T, Kamataki T. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 gene in Japanese. Pharm Res 1998; 15:517-24.

Yokoi T, Kosaka Y, Chida M et al. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics 1996; 6:395-401.

Yokono A, Morita S, Someya T, Hirokane G, Okawa M, Shimoda K. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. J Clin Psychopharmacol 2001; 21:549-55.

Yokooji T, Kida M, Mori M et al. Interaction of Rhei Rhizoma extract with cytochrome P450 3A and efflux transporters in rats. Pharmazie 2010; 65:367-74.

Yokose T, Doy M, Taniguchi T et al. Immunohistochemical study of cytochrome P450 2C and 3A in human non-neoplastic and neoplastic tissues. Virchows Arch 1999; 434:401-11.

Yokota H, Tamura S, Furuya H et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993; 3:256-63.

Yokota K, Hirano T, Urata N, Yamauchi N, Hattori MA. Upregulation of P-glycoprotein activity in porcine oocytes and granulosa cells during in vitro maturation. J Reprod Dev 2011; 57:322-6.

Yokota S, Higashi E, Fukami T, Yokoi T, Nakajima M. Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. Biochem Pharmacol 2011; 81:289-94.

Yokoyama S, Yokoyama R, Rotwein P. Molecular characterization of cDNA clones encoding the human alcohol dehydrogenase beta-1 and the evolutionary relationship to the other class I subunits alpha and gamma. Jpn J Genet 1987; 62:241-56.

Yokoyama U, Minamisawa S, Quan H et al. Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. J Clin Invest 2006; 116:3026-34.

Yoneda K, Matsumoto I, Sutoh F et al. In vitro metabolism and inhibitory effects of pranlukast in human liver microsomes. Biol Pharm Bull 2009; 32:688-93.

Yoneda M, Hotta K, Nozaki Y et al. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int 2009; 29:1078-85.

Yonezawa E, Matsumoto K, Ueno K et al. Lack of interaction between amiodarone and mexiletine in cardiac arrhythmia patients. J Clin Pharmacol 2002; 42:342-6.

Yong EL, Lim J, Qi W, Ong V, Mifsud A. Molecular basis of androgen receptor diseases. Ann Med 2000; 32:15-22.

Yong EL, Loy CJ, Sim KS. Androgen receptor gene and male infertility. Hum Reprod Update 2003; 9:1-7.

Yong WP, Innocenti F, Ratain MJ. The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol 2006; 62:35-46.

Yong WP, Kim TW, Undevia SD, Innocenti F, Ratain MJ. R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9. Eur J Cancer 2009; 45:1904-8.

Yongvanit P, Phanomsri E, Namwat N et al. Hepatic cytochrome P450 2A6 and 2E1 status in peri-tumor tissues of patients with Opisthorchis viverrini-associated cholangiocarcinoma. Parasitol Int 2011. doi:10. 1016/j. parint. 2011. 06. 026.

Yono M, Foster HE Jr, Shin D, Takahashi W, Pouresmail M, Latifpour J. Doxazosin-induced up-regulation of alpha 1A-adrenoceptor mRNA in the rat lower urinary tract. Can J Physiol Pharmacol 2004; 82:872-8.

Yoo B, Lemaire A, Mangmool S et al. Beta1-adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol 2009; 297:1377-86.

Yoo BK, Chen D, Su ZZ et al. Molecular mechanism of chemoresistance by astrocyte elevated gene-1. Cancer Res 2010; 70:3249-58.

Yoo EJ, Park SY, Cho NY et al. Influence of IL1B polymorphism on CpG island hypermethylation in Helicobacter pylori-infected gastric cancer. Virchows Arch 2010; 456:647-52.

Yoo HD, Cho HY, Lee YB. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1. Br J Clin Pharmacol 2010; 69:27-37.

Yoo HD, Kim MS, Cho HY, Lee YB. Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects. Eur J Clin Pharmacol 2011; 67:889-98.

Yoo HD, Lee SN, Kang HA, Cho HY, Lee IK, Lee YB. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10. Br J Pharmacol 2011; 164:433-43.

Yoo HH, Kim NS, Lee J, Sohn DR, Jin C, Kim DH. Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica 2009; 39:1-10.

Yoo HH, Lee SH, Jin C, Kim DH. Mechanism-based inactivation of cytochrome P450 3A4 by methylenedioxyphenyl lignans from Acanthopanax chiisanensis. Planta Med 2008; 74:822-7.

Yoon G, Kim TJ, Sung CO et al. Benign metastasizing leiomyoma with multiple lymph node metastasis: a case report. Cancer Res Treat 2011; 43:131-3.

Yoon S, Dubeau L, de Young M, Wexler N, Arnheim N. Huntington disease expansion mutations in humans can occur before meiosis is completed. Proc Nat Acad Sci USA 2003; 100:8834-8.

Yoon SL, Jung SI, Do EJ et al. Short rare hTERT-VNTR2-2nd alleles are associated with prostate cancer susceptibility and influence gene expression. BMC Cancer 2010; 10:393.

Yoon Y, Park HD, Park KU, Kim JQ, Chang YS, Song J. Associations between CYP2E1 promoter polymorphisms and plasma 1,3-dimethyluric acid/theophylline ratios. Eur J Clin Pharmacol 2006; 62:627-31.

Yoon YJ, Kim KB, Kim H et al. Characterization of benidipine and its enantiomers’ metabolism by human liver cytochrome P450 enzymes. Drug Metab Dispos 2007; 35:1518-24.

Yorifuji T, Kawakita R, Nagai S et al. Molecular and clinical analysis of Japanese patients with persistent congenital hyperinsulinism: predominance of paternally inherited monoallelic mutations in the KATP channel genes. J Clin Endocrinol Metab 2011; 96:141-5.

York TP, Vargas-Irwin C, Anderson WH, van den Oord EJ. Asthma pharmacogenetic study using finite mixture models to handle drug-response heterogeneity. Pharmacogenomics 2009; 10:753-67.

Yoshida A, Dave V, Ward RJ, Peters TJ. Cytosolic aldehyde dehydrogenase (ALDH1) variants found in alcohol flushers. Ann Hum Genet 1989; 53:1-7.

Yoshida H, Hastie CJ, McLauchland H, Cohen P, Goedert M. Phosphorylation of microtubule-association protein tau by isoforms of c-Jun N-terminal kinase (JNK). J Neurochem 2004; 90:352-8.

Yoshida K, Oida H, Kobayashi T et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Nat Acad Sci USA 2002; 99:4580-5.

Yoshida K, Takahashi H, Higuchi H et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004; 161:1575-80.

Yoshida M, Matsumoto T, Suzuki T, Kitamura S, Mayama T. Effect of concomitant treatment with a CYP3A4 inhibitor and a calcium channel blocker. Pharmacoepidemiol Drug Saf 2008; 17:70-5.

Yoshida M, Mori A, Morimoto S et al. Novel and potent calcium-sensing receptor antagonists: Discovery of (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahy dropyrazolo[1,5-a]pyrimidine-3-carboxamide monotosylate (TAK-075) as an orally active bone anabolic agent. Bioorg Med Chem 2011; 19:1881-94.

Yoshida N, Takada T, Yamamura Y, Adachi I, Suzuki H, Kawakami J. Inhibitory effects of terpenoids on multidrug resistance-associated protein 2- and breast cancer resistance protein-mediated transport. Drug Metab Dispos 2008; 36:1206-11.

Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon JT, Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 2003; 74:69-76.

Yoshida R, Nakajima M, Watanabe Y, Kwon JT, Yokoi T. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br J Clin Pharmacol 2002; 54:511-7.

Yoshida T, Kato K, Fujimaki T et al. Association of genetic variants with chronic kidney disease in Japanese individuals. Clin J Am Soc Nephrol 2009; 4:883-90.

Yoshida T, Kato K, Fujimaki T et al. Association of a polymorphism of the apolipoprotein E gene with chronic kidney disease in Japanese individuals with metabolic syndrome. Genomics 2009; 93:221-6.

Yoshida T, Kato K, Yokoi K et al. Association of genetic variants with chronic kidney disease in Japanese individuals with type 2 diabetes mellitus. Int J Mol Med 2009; 23:529-37.

Yoshida T, Yamauchi H, Fan Sun G. Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol Appl Pharmacol 2004; 198:243-52.

Yoshii K, Kobayashi K, Tsumuji M, Tani M, Shimada N, Chiba K. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci 2000; 67:175-84.

Yoshikado T, Takada T, Yamamoto T et al. Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4. Mol Pharmacol 2011; 79:241-50.

Yoshikai S, Sasaki H, Doh-ura K, Furuya H, Sakaki Y. Genomic organization of the human amyloid beta-protein precursor gene. Gene 1990; 87:257-63.

Yoshikawa M, Ikegami Y, Sano K et al. Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J Exp Ther Oncol 2004; 4:25-35.

Yoshikawa Y, Hosomi H, Fukami T, Nakajima M, Yokoi T. Establishment of knockdown of superoxide dismutase 2 and expression of CYP3A4 cell system to evaluate drug-induced cytotoxicity. Toxicol In Vitro 2009; 23:1179-87.

Yoshikawa Y, Morita M, Hosomi H et al. Knockdown of superoxide dismutase 2 enhances acetaminophen-induced hepatotoxicity in rat. Toxicology 2009; 264:89-95.

Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers-N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol 1995; 39:421-31.

Yoshimoto N, Nishiyama T, Toyama T et al. Genetic and environmental predictors, endogenous hormones and growth factors, and risk of estrogen receptor-positive breast cancer in Japanese women. Cancer Sci 2011; 102:2065-72.

Yoshimura M, Yasue H, Nakayama M et al. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 1998; 103:65-9.

Yoshimura R, Ueda N, Nakamura J. Low dosage of levomepromazine did not increase plasma concentrations of fluvoxamine. Int Clin Psychopharmacol 2000; 15:233-5.

Yoshimura T, Yoshimura M, Tabata A, Yasue H, Okamura H. The missense Glu298Asp variant of the endothelial nitric oxide synthase gene is strongly associated with placental abruption. Hum Genet 2001; 108:181-3.

Yoshinari K, Ueda R, Kusano K, Yoshimura T, Nagata K, Yamazoe Y. Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. Biochem Pharmacol 2008; 76:139-45.

Yoshitomi S, Ikemoto K, Takahashi J, Miki H, Namba M, Asahi S. Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicol In Vitro 2001; 15:245-56.

Yoshitsugu H, Nishimura M, Tateno C et al. Evaluation of human CYP1A2 and CYP3A4 mRNA expression in hepatocytes from chimeric mice with humanized liver. Drug Metab Pharmacokinet 2006; 21:465-74.

Yoshiyama Y, Zhang B, Bruce J, Trojanowskki JQ, Lee VM. Reduction of detryrosinated microtubules and Golgi fragmentation are linked to tau-induced degeneration in astrocytes. J Neurosci 2003; 23:10662-71.

Yoshizawa K, Umemura T, Ota M. Genetic background of autoimmune hepatitis in Japan. J Gastroenterol 2011; 46 Suppl 1:42-7.

Yoshizawa M, Hayashi H, Tashiro Y et al. Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients. Thromb Res 2009; 124:161-6.

Yoshizawa T, Yamakawa-Kobayashi K, Komatsuzaki Y et al. Dose-dependent association of apolipoprotein E allele epsilon-4 with late onset, sporadic Alzheimer’s disease. Ann Neurol 1994; 36:656-9.

Yost R, Pasquale TR, Sahloff EG. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection. Am J Health Syst Pharm 2009; 66:715-26.

You HS, Zhang HF, Dong YL et al. Absorption and transportation characteristics of scutellarin and scutellarein across Caco-2 monolayer model. Zhong Xi Yi Jie He Xue Bao 2010; 8:863-9.

You Y, Zhao W, Chen S et al. Association of TBX21 gene haplotypes in a Chinese population with systemic lupus erythematosus. Scand J Rheumatol 2010; 39:254-8.

Youdim KA, Lyons R, Payne L, Jones BC, Saunders K. An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point. J Pharm Biomed Anal 2008; 48:92-9.

Youdim KA, Zayed A, Dickins M et al. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br J Clin Pharmacol 2008; 65:680-92.

Youlten L. The effect of repeat dosing with cimetidine on the pharmacokinetics of intravenous granisetron in healthy volunteers. J Pharm Pharmacol 2004; 56:169-75.

Youmans KL, Leung S, Zhang J et al. Amyloid-β42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations. J Neurosci Methods 2011; 196:51-9.

Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 2001; 7:1798-804.

Young LC, Campling BG, Voskoglou-Nomikos T, Cole SP, Deeley RG, Gerlach JH. Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin Cancer Res 1999; 5:673-80.

Youngster I, Arcavi L, Schechmaster R et al. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 2010; 33:713-26.

Younis J, Cooper JA, Miller GJ, Humphries SE, Talmud PJ. Genetic variation in alcohol dehydrogenase 1C and the beneficial effect of alcohol intake on coronary heart disease risk in the Second Northwick Park Heart Study. Atherosclerosis 2005; 180:225-32.

Yousefi M, Karmaus W, Mudd LM et al. Expression of CYP19 and CYP17 is associated with leg length, weight, and BMI. Obesity 2011; 19:436-41.

Yousefipour G, Erfani N, Momtahan M, Moghaddasi H, Ghaderi A. CTLA4 exon 1 and promoter polymorphisms in patients with multiple sclerosis. Acta Neurol Scand 2009; 120:424-9.

Youssef DM, Elbehidy RM, Abdelhalim HS, Amr GE. Soluble interleukine-2 receptor and MDR1 gene expression levels as inflammatory biomarkers for prediction of steroid response in children with nephrotic syndrome. Iran J Kidney Dis 2011; 5:154-61.

Yu A, Haining RL. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos 2001; 29:1514-20.

Yu A, Kneller BM, Rettie AE, Haining RL. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6. 1, 2D6. 2, 2D6. 10, and 2D6. 17 allelic isoforms. J Pharmacol Exp Ther 2002; 303:1291-300.

Yu AM. Indolealkylamines: biotransformations and potential drug-drug interactions. AAPS J 2008; 10:242-53.

Yu AM, Fukamachi K, Krausz KW, Cheung C, Gonzalez FJ. Potential role for human cytochrome P450 3A4 in estradiol homeostasis. Endocrinology 2005; 146:2911-9.

Yu AM, Haining RL. Expression, purification, and characterization of mouse CYP2d22. Drug Metab Dispos 2006; 34:1167-74.

Yu AM, Idle JR, Byrd LG, Krausz KW, Küpfer A, Gonzalez FJ. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003; 13:173-81.

Yu AM, Idle JR, Krausz KW, Küpfer A, Gonzalez FJ. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther 2003; 305:315-22.

Yu B, Handelsman DJ. Pharmacogenetic polymorphisms of the AR and metabolism and susceptibility to hormone-induced azoospermia. J Clin Endocrinol Metab 2001; 86:4406-11.

Yu BN, Chen GL, He N et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos 2003; 31:1255-9.

Yu C, Shin YG, Kosmeder JW, Pezzuto JM, van Breemen RB. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun Mass Spectrom 2003; 17:307-13.

Yu C, Ye S, Sun H et al. PXR-mediated transcriptional activation of CYP3A4 by cryptotanshinone and tanshinone IIA. Chem Biol Interact 2009; 177:58-64.

Yu CP, Wu PP, Hou YC et al. Quercetin and rutin reduced the bioavailability of cyclosporine from neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4. J Agric Food Chem 2011; 59:4644-8.

Yu D. Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol 2001; 28(5 Suppl 16):12-7.

Yu D, Jing T, Liu B et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998; 2:581-91.

Yu D, Liu B, Jing T et al. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 1998; 16:2087-94.

Yu H, Bowden DW, Spray BJ, Rich SS, Freedman BI. Linkage analysis between loci in the renin-angiotensin axis and end-stage renal disease in African Americans. J Am Soc Nephrol 1996; 7:2559-64.

Yu H, Hu YQ, Ip FC, Zuo Z, Han YF, Ip NY. Intestinal transport of bis(12)-hupyridone in Caco-2 cells and its improved permeability by the surfactant Brij-35. Biopharm Drug Dispos 2011; 32:140-50.

Yu H, Lin S, Liu G, Zhang Y, Deng C, Ma W. T1198C polymorphism of the angiotensinogen gene and antihypertensive response to angiotensin-converting enzyme inhibitors. Hypertens Res 2005; 28:981-6.

Yu H, Tu Y, Zhang C et al. Evodiamine as a novel antagonist of aryl hydrocarbon receptor. Biochem Biophys Res Commun 2010; 402:94-8.

Yu H, Wang Y, Pattwell S et al. Variant BDNF Val66Met polymorphism affects extinction of conditioned aversive memory. J Neurosci 2009; 29:4056-64.

Yu H, Zhang Y, Liu G. Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients. Hypertens Res 2003; 26:881-6.

Yu HH, Liu PH, Lin YC et al. Interleukin 4 and STAT6 gene polymorphisms are associated with systemic lupus erythematosus in Chinese patients. Lupus 2010; 19:1219-28.

Yu HS, Oyama T, Isse T et al. Formation of acetaldehyde-derived DNA adducts due to alcohol exposure. Chem Biol Interact 2010; 188:367-75.

Yu IW, Bukaveckas BL. Pharmacogenetic tests in asthma therapy. Clin Lab Med 2008; 28:645-65.

Yu J, Brown DG, Burdette D. In vitro metabolism studies of nomifensine monooxygenation pathways: metabolite identification, reaction phenotyping, and bioactivation mechanism. Drug Metab Dispos 2010; 38:1767-78.

Yu J, Buslig BS, Haun C, Cancalon P. New furanocoumarins detected from grapefruit juice retentate. Nat Prod Res 2009; 23:498-506.

Yu J, Paine MJ, Maréchal JD et al. In silico prediction of drug binding to CYP2D6: identification of a new metabolite of metoclopramide. Drug Metab Dispos 2006; 34:1386-92.

Yu JC, Hsiung CN, Hsu HM et al. Genetic variation in the genome-wide predicted estrogen response element-related sequences is associated with breast cancer development. Breast Cancer Res 2011; 13:13.

Yu JH, Bigler J, Whitton J, Potter JD, Ulrich CM. Mismatch repair polymorphisms and colorectal polyps: hMLH1-93G>A variant modifies risk associated with smoking. Am J Gastroenterol 2006; 101:1313-9.

Yu JT, Yu NN, Gao SS et al. Neuropeptide Y polymorphisms and ischemic stroke in Chinese population. Clin Chim Acta 2010; 411:242-5.

Yu K, Zhang J, Zhang J et al. Methionine synthase A2756G polymorphism and cancer risk: a meta-analysis. Eur J Hum Genet 2010; 18:370-8.

Yu KD, Di GH, Fan L et al. A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer. FASEB J 2009; 23:2274-87.

Yu KD, Rao NY, Chen AX, Fan L, Yang C, Shao ZM. A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk. Breast Cancer Res Treat 2011; 126:37-45.

Yu KS, Cho JY, Jang IJ et al. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 2004; 76:104-12.

Yu KS, Yim DS, Cho JY et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001; 69:266-73.

Yu L, Huang Z, Mariani J, Wang Y, Moskowitz M, Chen JF. Selective inactivation or reconstitution of adenosine A2a receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat Med 2004; 10:1081-7.

Yu L, Lu S, Lin Y, Zeng S. Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol 2007; 73:1842-51.

Yu M, Xu XJ, Yin JY et al. KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes. Clin Pharmacol Ther 2010; 87:330-5.

Yu M, Zhang W, Qin L, Tian L, Zhou C. Enhancement of P-glycoprotein expression by hepatocyte transplantation in carbon tetrachloride-induced rat liver. Anat Rec 2010; 293:1167-74.

Yu N, Di Q, Liu H et al. Nuclear factor-kappa B activity regulates brain expression of p-glycoprotein in the kainic acid-induced seizure rats. Mediators Inflamm 2011. doi:10. 1155/2011/670613.

Yu NN, Yu JT, Xiao JT et al. Tau-tubulin kinase-1 gene variants are associated with Alzheimer’s disease in Han Chinese. Neurosci Lett 2011; 491:83-6.

Yu PF, Wang WY, Eerdun G et al. The role of P-glycoprotein in transport of Danshensu across the blood-brain barrier. Evid Based Complement Alternat Med 2011. doi:10. 1155/2011/713523.

Yu Q, Guo J, Zhou J. A minimal leght between tau exon 10 and 11 is required for correct splicing of exon 10. J Neurochem 2004; 90:164-72.

Yu RZ, Geary RS, Flaim JD et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2’-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 2009; 48:39-50.

Yu S, Yu Y, Liu L et al. Increased plasma exposures of five protoberberine alkaloids from Coptidis Rhizoma in streptozotocin-induced diabetic rats: is P-GP involved? Planta Med 2010; 76:876-81.

Yu S, Zhang Y, Yuen MT, Zou C, Danielpour D, Chan FL. 17-Beta-estradiol induces neoplastic transformation in prostatic epithelial cells. Cancer Lett 2011; 304:8-20.

Yu SF, Zhou WH, Jiang KY, Gu GZ, Wang S. Job stress, gene polymorphism of beta2-AR, and prevalence of hypertension. Biomed Environ Sci 2008; 21:239-46.

Yu ST, Chen TM, Tseng SY, Chen YH. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem Biophys Res Commun 2007; 358:79-84.

Yu T, Parks BW, Yu S et al. Iron-Ion radiation accelerates atherosclerosis in apolipoprotein E-deficient mice. Radiat Res 2011; 175:766-73.

Yu W, Hu C, Zhang R et al. Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 Diabetes. Clin Pharmacol Ther 2011; 89:437-42.

Yu WP, Lou M, Deng B, Song HM, Wang HB. Beta1-adrenergic receptor (Arg389Gly) polymorphism and response to bisoprolol in patients with chronic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 2006; 34:776-80.

Yu XN, Li H, Chen XL, Li XX, Wang R, Gao F. Study on reversing mechanism of multidrug resistance of K562/A02 cell line by carnosic acid. Zhonghua Xue Ye Xue Za Zhi 2010; 31:381-4.

Yu Y, Niu T, Venners SA et al. Associations of baseline blood pressure levels and efficacy of Benazepril treatment with interaction of alpha-adducin and ACE gene polymorphisms in hypertensives. Clin Exp Hypertens 2005; 27:83-94.

Yu Y, Reynolds R, Fagerness J, Rosner B, Daly MJ, Seddon JM. Association of variants in LIPC and ABCA1 genes with intermediate and large drusen and advanced age-related macular degeneration. Invest Ophthalmol Vis Sci 2011; 52:4663-70.

Yu YW, Tsai SJ, Liou YJ, Hong CJ, Chen TJ. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol 2006; 16:498-503.

Yu Z, Li S, Nguyen H, Li X. Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum Molec Genet 2002; 11:905-14.

Yuan A, Kumar A, Peterhoff C, Duff K, Nixon RA. Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J Neurosci 2008; 28:1682-7.

Yuan F, Chen J, Wu WJ et al. Effects of matrine and oxymatrine on catalytic activity of cytochrome P450s in rats. Basic Clin Pharmacol Toxicol 2010; 107:906-13.

Yuan H, Lu LJ, Du YZ, Hu FQ. Stearic acid-g-chitosan polymeric micelle for oral drug delivery: in vitro transport and in vivo absorption. Mol Pharm 2011; 8:225-38.

Yuan H, Pan HF, Li LH et al. Meta analysis on the association between FcgammaRIIa-R/H131 polymorphisms and systemic lupus erythematosus. Mol Biol Rep 2009; 36:1053-8.

Yuan H, Qian Y, Xu Y et al. Cosegregation of the G7444A mutation in the mitochondrial COI/tRNA(Ser(UCN)) genes with the 12S rRNA A1555G mutation in a Chinese family with aminoglycoside-induced and nonsyndromic hearing loss. Am J Med Genet A 2005; 138:133-40.

Yuan H, Yu M, Yang Y, Wu K, Lin X, Li J. Association of CYP2D6 single-nucleotide polymorphism with response to ophthalmic timolol in primary open-angle Glaucoma-a pilot study. J Ocul Pharmacol Ther 2010; 26:497-501.

Yuan J, Guo S, Hall D et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 2011; 25:1271-80.

Yuan J, Liu L, Shimada M et al. Induction, expression and maintenance of cytochrome P450 isoforms in long-term cultures of primary human hepatocytes. ALTEX 2004; 21 Suppl 3:3-11.

Yuan J, Lv H, Peng B, Wang C, Yu Y, He Z. Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol 2009; 63:1103-10.

Yuan J, Tang W, Chun Y, Ying H, Yang Y, Xiao C. Angiotensinogen T174M and M235T variants and hypertension in the Hani and Yi minority groups of China. Biochem Genet 2009; 47:344-50.

Yuan JH, Cheng JQ, Jiang LY et al. Breast cancer resistance protein expression and 5-fluorouracil resistance. Biomed Environ Sci 2008; 21:290-5.

Yuan JH, Li YQ, Yang XY. Protective effects of epigallocatechin gallate on colon preneoplastic lesions induced by 2-amino-3-methylimidazo[4,5-f ] quinoline in mice. Mol Med 2008; 14:590-8.

Yuan JH, Stolzenbach JC, Salamon CM, Snook SS, Schoenhard GL. Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. Xenobiotica 1997; 27:489-97.

Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 2002; 30:1311-9.

Yuan W, Jin H, Chung JK, Zheng J. Evidence for cellular protein covalent binding derived from styrene metabolite. Chem Biol Interact 2010; 186:323-30.

Yuan ZH, Liu Q, Zhang Y, Liu HX, Zhao J, Zhu P. CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility. Ann Hematol 2011; 90:293-9.

Yuasa I, Umetsu K, Vogt U et al. Human orosomucoid polymorphism: molecular basis of the three common ORM1 alleles, ORM1*F1, ORM1*F2, and ORM1*S. Hum Genet 1997, 99:393-8.

Yubero-Lahoz S, Pardo R, Farré M et al. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. Clin Pharmacokinet 2011; 50:319-29.

Yue J, Dong G, He C, Chen J, Liu Y, Peng R. Protective effects of thiopronin against isoniazid-induced hepatotoxicity in rats. Toxicology 2009; 264:185-91.

Yue J, Khokhar J, Miksys S, Tyndale RF. Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake. Eur J Pharmacol 2009; 609:88-95.

Yue J, Miksys S, Hoffmann E, Tyndale RF. Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course. J Psychiatry Neurosci 2008; 33:54-63.

Yue L, Mazzone T. Endogenous adipocyte apolipoprotein E is colocalized with caveolin at the adipocyte plasma membrane. J Lipid Res 2011; 52:489-98.

Yue L, Saikawa Y, Ota K et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 2003; 13:29-38.

Yue QY, Säwe J. Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol 1997; 52:41-7.

Yue QY, Zhong ZH, Tybring G et al. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1998; 64:384-90.

Yue W, Fang X, Zhang C et al. Two novel SNPs of the ABCG2 gene and its associations with milk traits in Chinese Holsteins. Mol Biol Rep 2011; 38:2927-32.

Yueh MF, Kawahara M, Raucy J. High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line. Drug Metab Dispos 2005; 33:38-48.

Yuen YP, Lai CK, Tong GM et al. Novel mutations of the AGXT gene causing primary hyperoxaluria type 1. J Nephrol 2004; 17:436-40.

Yukawa E, Hokazono T, Yukawa M et al. Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients. Clin Pharmacokinet 2002; 41:153-9.

Yukawa E, Ichimaru R, Maki T et al. Interindividual variation of serum haloperidol concentrations in Japanese patients-clinical considerations on steady-state serum level-dose ratios. J Clin Pharm Ther 2003; 28:97-101.

Yukinaga H, Takami T, Shioyama SH et al. Identification of cytochrome P450 3A4 modification site with reactive metabolite using linear ion trap-Fourier transform mass spectrometry. Chem Res Toxicol 2007; 20:1373-8.

Yumibe N, Huie K, Chen KJ, Snow M, Clement RP, Cayen MN. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol 1996; 51:165-72.

Yun CH, Lee HS, Lee HY et al. Roles of human liver cytochrome P450 3A4 and 1A2 enzymes in the oxidation of myristicin. Toxicol Lett 2003; 137:143-50.

Yun JH, Lee SB, Lee HJ et al. Bi-functional induction of the quinone reductase and cytochrome P450 1A1 by youngiasides via Nrf2-ARE and AhR-XRE pathways. Biol Pharm Bull 2010; 33:1650-7.

Yun KU, Oh SJ, Oh JM et al. Age-related changes in hepatic expression and activity of cytochrome P450 in male rats. Arch Toxicol 2010; 84:939-46.

Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, Jope RS. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol 2010; 79:632-46.

Yvan-Charvet L, Kling J, Pagler T et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010; 30:1430-8.

Yvan-Charvet L, Pagler T, Gautier EL et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 2010; 328:1689-93.

Yvan-Charvet L, Pagler TA, Seimon TA et al. ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis. Circ Res 2010; 106:1861-9.